

An Ounce of Detection is Worth... 60,000 Lives Saved

FOCUS ON: COLON CANCER

This issue of momentum focuses on a new, less invasive screening method for colon cancer and the dedicated young Damon Runyon physician-scientist leading the charge.

A colon cancer diagnosis should not be a death sentence. When detected early, colon cancer is curable about 95% of the time. Years of basic research have revealed that most colon cancers grow slowly and are easily identified in the earliest stages by simple procedures. So, why is it that colon cancer ranks as the second most deadly cancer, estimated to take the lives of nearly 60,000 Americans in 2006?

According to colon cancer expert and Damon Runyon Clinical Investigator Dr. William M. Grady, the answer is simple — far too few people undergo a colonoscopy once they reach age 50. The reasons are clear. We know that colonoscopy can be, let's just say, unpleasant and inconvenient. And, for many, it is simply too expensive. So, people tend to wait until symptoms are so severe that they cannot be ignored or until Medicare coverage begins in their mid-60s.

What is lost by not undergoing screening? According to Dr. Grady, nothing less than a chance for a cure. One of the biggest challenges in the care of colon cancer patients is the treatment of advanced disease. If not caught early, benign growths or polyps have time to grow, turn into colon cancer, and spread. Once this occurs, the chances for a cure plummet. In contrast, when diagnosed at an early stage, almost all patients survive. "Looking at it that way," says Dr. Grady, "the risk of not being screened far outweighs the 'yuck' factor of conventional screening."

Frustrated by the poor compliance with colon cancer screening guidelines, Dr. Grady became convinced that the greatest need in the colon cancer field was the development of a more palatable way to identify early stage disease. After just four years of funding by the Damon Runyon Foundation, he is well on his way to doing just that.

Dr. Grady's approach takes advantage of knowledge gained from decades of basic research which revealed that DNA from cells in colon polyps and early stage cancer has telltale changes that distinguish it from DNA in normal cells. The abnormality is called DNA methylation and causes a gene to be turned off, or silenced. In colon cancer, as in many other cancers, silencing of certain genes important for normal cell growth and survival is linked to tumor development. Dr. Grady and others already have identified candidate genes which, when methylated, are associated with early-stage colorectal cancer.

Bill reasoned that if he could develop a method to detect these methylated genes in a blood or stool sample, it would eliminate the need for patients to undergo an invasive procedure to detect polyps. So far, his research shows real promise for delivering a



Dr. William Grady is developing a new, less invasive colon cancer screening test.

commercial blood or stool sample test for colon polyps. Bill believes the new test will be available within the next 5-10 years. Once marketed, Dr. Grady's test would likely encourage more people to undergo screening. It also would limit the use of costly, more invasive procedures to only those patients found to be at risk for cancer by the methylation test.

Bill's interest in developing more accessible screening methods is timely. As baby boomers enter their 50s and 60s, the numbers of colon cancer diagnoses are likely to climb. He stresses there are other ways the general population can decrease risk, including eating a healthy diet, not smoking, and getting moderate exercise. But, for some families, the need for reliable and accessible screening measures is more urgent. For these families, a life-threatening colon cancer diagnosis is more of a guarantee than a possibility. This is where Dr. Grady envisions his early detection testing to be the most critical. Jan Galbraith*, mother of two and one of Dr. Grady's patients, could not agree more. Jan lost her Mom to colon cancer, and her sister was diagnosed at 37. Since then, Jan, both her nieces, and one of her children have all had cancerous or precancerous polyps removed. In fact, her daughter was just 21 when she had her first surgical removal of precancerous polyps. "Colon cancer is part of our family's reality. But even with our family history, not everyone sees the risk of not being screened. It is awfully hard to convince a healthy, young person to undergo a colonoscopy."

Dr. Grady's approach exemplifies the mission of the Damon Runyon Clinical Investigator program, which aims to move discoveries of basic cancer biology out of the laboratory and into the clinic.

"If I can offer my patients a reliable and accessible method for early detection, maybe the next generations will not have to suffer from this horrible disease. Regardless of genetic predisposition, no one has to die from colon cancer — it is preventable and treatable if it's caught early."

As for the Galbraith family, everyone remains cancer free — so far. Jan continues her yearly screening program and encourages her family, even the younger members, to get screened early, before the colon cancer that claimed her mother's life can take hold in the next generations. "So many cancer patients have no way of knowing a tumor was growing inside them until it is too late. I tell my kids, we have been given a gift. We know the risk and Dr. Grady is a great doctor with the tools to stop this in its tracks. Let's not let colon cancer sneak up on us."

*The name of the patient has been changed to protect her identity.

DAMON RUNYON SUPPORTS RESEARCH IN EARLY DETECTION

Recently, the National Center for Health Statistics reported that the number of cancer deaths in the United States dropped in 2003 — the first time this has occurred since 1930, the year such statistics were first tracked. One major factor underlying this dramatic achievement is more effective early detection methods. Screening tests such as mammography, prostate specific antigen (PSA) testing, and colonoscopy are now commonplace. Once again, Damon Runyon supported scientists are on the cutting edge, this time developing the next generation of early detection methods for a variety of cancers.

- Pierre Massion, MD, Vanderbilt University Medical Center — Identifying the molecular signature of precancerous lung tumors
- Albert Koong, MD, PhD, Stanford University School of Medicine — Developing a specific blood or serum marker for pancreatic cancer
- Matthew Meyerson, MD, PhD, Dana-Farber Cancer Institute — Genomic screening to facilitate more accurate and earlier diagnoses of all cancers
- Christine Chung, MD, Vanderbilt University Medical Center — Discovering the genetic clues to early stage head and neck cancers

60th Anniversary Breakfast Benefit

RAISES \$1.2 MILLION FOR CANCER RESEARCH

Our Foundation was started with Walter Winchell's call over the radio, asking Mr. and Mrs. America to join the fight against cancer. On June 13th, our 60th Anniversary Breakfast Benefit honored another radio great: Mel Karmazin, Chief Executive Officer of Sirius Satellite Radio. During the breakfast, the call was raised again—this time with a radio broadcast about the Foundation made by Martha Stewart on her Sirius Radio program. Guests heard from one of the world's preeminent scientists, David Baltimore, PhD, Noble Laureate and President of California Institute of Technology and Erin Zammett Ruddy, cancer patient, advocate, and Glamour Features Editor. Just as in 1946, 100% of the dollars raised at the breakfast will go to support the brightest young minds in cancer research around the country.

Right: Damon Runyon Board Member and Chairman and CEO of NBC Universal Bob Wright (R) congratulates Honoree Mel Karmazin (L).



BAY AREA EVENT HELD

On May 24th, the Damon Runyon Cancer Research Foundation hosted a cocktail reception at the Stanford University Comprehensive Cancer Center. Guests learned of the significant role the Foundation plays in identifying and supporting top young cancer researchers in the Bay Area, with an investment of over \$13 million to date. Special guest speaker **Ronald Levy, MD**, chief of the Division of Oncology at Stanford and member of our Board, talked about the importance of funding young minds and the Foundation's exceptional track record for selecting future stars. Many thanks to Connie and Bob Lurie for their pivotal role in organizing this sensational evening!

THEATRE BENEFITS ARE A **great evening out**



Our April theatre benefit featuring *Three Days of Rain*, starring Julia Roberts, was a huge success. At dinner, Richard Gephardt, former Majority Leader of the House of Representatives and Presidential candidate, shared his family's personal experience with cancer and his commitment to cancer research. Thanks to Board Member Karen Seitz for inviting such a fascinating guest.

Tickets for our next theatre benefit featuring *Mary Poppins* on November 9, 2006 are available — call 212.455.0501 to reserve your tickets now!

GO VERTICAL

THE ABSOLUTELY URBAN CLIMB FOR CANCER

GO VERTICAL GOES WEST

Go Vertical headed to beautiful Aspen, Colorado this summer for our inaugural climb to the top of Aspen Mountain. Damon Runyon champion, Colt Landreth, did an amazing job recruiting almost 100 participants — and their dogs — to hike 3.25 miles to the 11,000-foot summit, raising over \$10,000!



PHOTO: Karen Keeney, Aspen



Left: Two-time cancer survivor and Go Aspen 2006 Climber Alex Arnfield. Above: Climbers starting the trek to the 11,000-foot summit



GO VERTICAL CHICAGO
NOVEMBER 12, 2006
*
GO VERTICAL BOSTON
EARLY 2007

Go Vertical Chicago 2006 and Go Vertical Boston 2007 are shaping up to be better than ever! We hope to top our record with more than 2,000 people participating in the two stair-climbs up the Sears Tower (November 12, 2006) and the John Hancock Tower (Early 2007). Registration is now open for Go Vertical Chicago at GoVerticalChicago.org. Register today!

DONOR spotlight



Jane's Ride Across America

Imagine being told you have six months to live and then deciding to run your first marathon. That's the kind of person Jane Tomlinson is. Six years later, she continues to defy the odds and battle the metastatic breast cancer that she knows, at some point, will take her life. Despite her prognosis, Jane is determined to change the odds for future cancer patients. This summer she arrived from her home town in Leeds, England, with her family at her side, to bicycle across the United States and raise dollars for cancer research. We were honored that Jane selected the Damon Runyon Cancer Research Foundation as her U.S. charity. Starting in San Francisco, Jane pedaled across the Rockies, through the Great Plains, into big cities and small towns, battling extreme heat, high winds and some ferocious dogs along the way. On September 1ST she rode triumphantly into New York City. The ride was a tremendous challenge for Jane, who struggled with her illness everyday. It's not too late to show your support for Jane and her heroic cross-country journey to benefit the Damon Runyon Cancer Research Foundation. Visit our website at www.drcrf.org or call 1-877-7CANCER today.

You're Awesome Jane!

new awardees

f 18 New Damon Runyon Fellows Selected

The Damon Runyon Fellowship Award supports the training of the brightest young postdoctoral scientists by established investigators in leading laboratories across the country. In May, the Foundation's Scientific Advisory Committee chose 18 new Fellows for the 3 year award designed to enlist the skills and creativity of the next generation in the fight against cancer.

Anirban Banerjee, PhD

"Structural and mechanistic analysis of hERG channel function" with Roderick MacKinnon, MD, The Rockefeller University, New York, New York

Duhee Bang, PhD

"The mirror image *in vitro* selection of L-DNA aptamers for the identification of cancer therapeutics" with George Church, PhD, Harvard Medical School, Boston, Massachusetts

Gloria B. Choi, PhD

"Modulation of feeding behavior by external and internal factors" with Richard Axel, MD, Columbia University, New York, New York

Frauke Drees, PhD

"Role of SSeCKS in Mena-driven tumor cell invasion" with Frank B. Gertler, PhD, Massachusetts Institute of Technology, Cambridge, Massachusetts

***Wendy S. Garrett, MD, PhD**

"Mechanisms and modulators of T-bet and the innate immune system in inflammation-associated colon cancer" with Laurie H. Glimcher, MD, Harvard School of Public Health, Boston, Massachusetts

Marnie E. Gelbart, PhD

"Recognizing the X chromosome for dosage compensation" with Mitzi I. Kuroda, PhD, Brigham & Women's Hospital, Boston, Massachusetts

Guobin He, PhD

"Role of IKKbeta in tobacco smoking-induced lung carcinogenesis" with Michael Karin, PhD, University of California, San Diego, California

Reginald Hill, PhD

"Exploring the underlying genetic mechanisms of pancreatic cancer development" with Hong Wu, MD, PhD, University of California, Los Angeles, California

Brendan N. Lilley, PhD

"Regulation of neuronal polarity and synapse formation by mammalian SAD kinases" with Joshua Sanes, PhD, Harvard University, Cambridge, Massachusetts

Patrick James Lupardus, PhD

"Reconstitution and imaging of the Jak1 kinase in complex with the IL-6 cytokine receptor gp130" with K. Christopher Garcia, PhD, Stanford University, Stanford, California

David Maag, PhD

"The function of inositol polyphosphate multikinase in the regulation of cell growth and proliferation" with Solomon H. Snyder, MD, Johns Hopkins University, Baltimore, Maryland

Patrick T. McGrath, PhD

"Molecular analysis of a metastable behavioral state in *Caenorhabditis elegans*" with Cornelia I. Bargmann, PhD, The Rockefeller University, New York, New York

Kathryn A. O'Donnell, PhD

"Identification of hepatocellular carcinoma susceptibility genes using retrotransposon-mediated mutagenesis" with Jef D. Boeke, PhD, Johns Hopkins University, Baltimore, Maryland

Ian Schneider, PhD

"Lamellipodium-Lamella communication during epidermal growth factor-mediated chemotaxis" with Clare M. Waterman-Storer, PhD, The Scripps Research Institute, La Jolla, California

***Matthew G. Vander Heiden, MD, PhD Mel Kamazin Fellow**

"Regulation of glycolytic metabolism in proliferating cells by pyruvate kinase" with Lewis C. Cantley, PhD, Harvard Medical School, Boston, Massachusetts

Qian Wang, PhD

"TFIID recruitment and coordinate regulation of ribosomal protein (RP) genes" with Kevin Struhl, PhD, Harvard Medical School, Boston, Massachusetts

Monte Winslow, PhD Merck Fellow

"Identification and functional characterization of genes required for invasion and metastasis by analysis of clonally related primary and secondary tumors" with Tyler Jacks, PhD, Massachusetts Institute of Technology, Cambridge, Massachusetts

Xiaoyan Zheng, PhD

"The iHog family receptors in hedgehog signal response" with Philip A. Beachy, PhD, Johns Hopkins University, Baltimore, Maryland

* *Physician-Scientist* - \$170,000 *Basic Scientist* - \$134,000

ci 5 New Damon Runyon Clinical Investigators Selected

The Damon Runyon Clinical Investigator Award supports early career physician-scientists conducting patient-oriented research. The goal of this innovative program is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient's bedside in search of breakthrough treatments. In May, the Damon Runyon Clinical Investigator Award Committee selected five exceptional investigators to receive the \$450,000 award.

Renier J. Brentjens, MD, PhD

Damon Runyon-Lilly Clinical Investigator

"Adoptive therapy of B cell leukemias with genetically modified autologous T cells" with Michel Sadelain, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, New York

Patrick A. Brown, MD

Damon Runyon-Lilly Clinical Investigator

"Translating FLT3 inhibition into improved outcome for high risk childhood leukemia" with Donald Small, MD, PhD, Johns Hopkins University, Baltimore, Maryland

Delphine L. Chen, MD

"Apoptosis imaging" with Michael J. Welch, PhD, Washington University School of Medicine, St. Louis, Missouri

Andrea L. Cox, MD, PhD

"Analysis and manipulation of cross reactive immune responses to partial escape mutations in chronic Hepatitis C virus infection" with Drew M. Pardoll, MD, PhD, Johns Hopkins University, Baltimore, Maryland

Loren S. Michel, MD

Damon Runyon-Lilly Clinical Investigator

"Characterization of the Trop-2 receptor in breast cancer progression" with Matthew J. Ellis, MB, PhD, Washington University School of Medicine, St. Louis, Missouri

Congratulations to all!

science news

60 YEARS OF FUELING DISCOVERY: THE LEGACY OF THE DAMON RUNYON CANCER RESEARCH FOUNDATION

Since its inception, the Damon Runyon Foundation has sought the best and the brightest young scientists, regardless of gender, race, or nationality. Walter Winchell's approach to funding was visionary:

"An army of well trained men and women will eventually move to all parts of the world to advance research, to train others, and to help detect and control cancer."

"The Fund, like cancer, does not acknowledge any geographical boundaries—nor does race, color or creed play any part in the determination of its allocations."

For many young female scientists, funding from the Damon Runyon Foundation provided the boost they needed to jump-start their careers. In honor of our 60th Anniversary, here is a look back at some of the notable female scientists funded by the Damon Runyon Cancer Research Foundation over our history. Today we are proud that women make up one-third of the scientists we support.

Rose Ruth Ellison, MD (Damon Runyon Fellow '52-'53)

participated in the earliest trials of methotrexate, a drug now widely used to treat a variety of cancers. Dr. Ellison was the first woman to serve as President of the American Society of Clinical Oncology, the professional society of cancer specialists.

Carol Prives, PhD (Damon Runyon Fellow '68-'70)

is internationally recognized for her work on the p53 tumor suppressor gene, a key regulator of cancer development. Dr. Prives is the DaCosta Professor of Biology and in the Department of Biological Sciences at Columbia University and also served as a member of the Damon Runyon Scholar Award Review Panel.

Philippa Marrack, PhD (Damon Runyon Fellow '71-'73)

one of the world's preeminent immunologists, has made numerous discoveries including seminal work in how cancer evades the immune system. Dr. Marrack is an investigator with the Howard Hughes Medical Institute, a member of the Department of Medicine at the National Jewish Center for Immunology and Respiratory Medicine,

and distinguished Professor of Biochemistry, Biophysics, and Genetics and of Immunology and Medicine at the University of Colorado Health Sciences Center.

Elaine Fuchs, PhD (Damon Runyon Fellow '77-'79)

a pioneer in stem cell biology, uncovered the genetic basis of blistering skin diseases and clues to the way skin cancer develops. Dr. Fuchs is an investigator of the Howard Hughes Medical Institute and the Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development at The Rockefeller University in New York. Dr. Fuchs serves on the Foundation's Board of Directors.

Helen Piwnica-Worms, PhD (Damon Runyon Fellow '84-'85)

is leading the field in understanding how cancer cells bypass the usual checks on cell division, leading to uncontrolled cell growth and cancer. Dr. Piwnica-Worms is a Professor of Cell Biology and Physiology and Internal Medicine at Washington University in St. Louis and an investigator of the Howard Hughes Medical Institute. She serves as the Vice-Chair of the Foundation's Scientific Advisory Committee.

"Being awarded a prestigious fellowship from the Damon Runyon Foundation provided a tremendous boost as I transitioned into the cancer field. To me it meant that the leaders and visionaries in cancer research that comprised the selection committee were saying, 'We believe in you, we support you—go for it!' and there has been no turning back."

—Helen Piwnica-Worms, PhD

AWARDS & ACCOLADES

John E. Niederhuber, MD (Damon Runyon Grantee '75)

was appointed by President Bush as the 13th Director of the National Cancer Institute (NCI). Dr. Niederhuber, who has had a highly successful career as a talented cancer surgeon, innovative researcher, and cancer center director, now leads our nation's battle against cancer.

John L. Rinn, PhD (Damon Runyon Fellow '05-'08) and Howard Y. Chang, MD, PhD (Kenneth G. and Elaine A. Langone Damon Runyon Scholar '06-'08)

were featured in *The New York Times* and *Newsday* for their discovery of a kind of "blue print" system that defines each cell's position in the body. Ultimately, these "blue prints" could have a profound impact on how cancer cells are tracked, identifying the spread of tumor cells earlier and more efficiently.

Scott A. Armstrong, MD, PhD (Damon Runyon-Lilly Clinical Investigator '03-'08)

and colleagues have isolated rare cancer stem cells that cause leukemia in mouse models of the disease. This is an important finding, because it indicates that normal stem cells can be distinguished from leukemia stem cells and spared during cancer treatment.

Michael R. Botchan, PhD (Damon Runyon Fellow '72-'75)

was elected to the American Academy of Arts and Sciences.

The Academy is an international society of scholars that elects exceptional achievers from varied disciplines including science, scholarship, business, public affairs, and the arts.

Antonina Roll-Mecak, PhD (Damon Runyon Fellow '03-'06) received the L'Oreal Women in Science Fellowship Award.

David W. Russell, PhD (Damon Runyon Fellow '80-'82)

from UT Southwestern Medical Center, Dallas and **Richard M. Amasino, PhD (Damon Runyon Fellow '82-'83)** from the University of Wisconsin, Madison were inducted into the National Academy of Sciences (NAS), one of the highest honors for a U.S. scientist.

Lei Wang, PhD (Damon Runyon Fellow '03-'05)

has been named to the Searle Scholar program, one of the most prestigious awards available to young faculty working in the life sciences.

Helen Piwnica-Worms, PhD (Damon Runyon Fellow '84-'85)

and **Edison Liu, MD (Damon Runyon Fellow '83-'84)** were elected to the Board of Directors of the American Association of Cancer Research.

For information about recent discoveries made by Damon Runyon scientists, please visit the "News" section on our website (www.drclf.org).

What are the hottest areas in cancer research? How are scientists from the Damon Runyon Cancer Research Foundation making an impact now and shaping the future of cancer research? Look for the next issue of *momentum*, coming in Spring 2007.

momentum PHOTO GALLERY



roll out the barrel!

Carried during the University of Florida Homecoming parade in the fall of 1951, people all over the Sunshine State gave generously to the Damon Runyon Fund and sent a "barrel of money" into cancer research labs across the country. Throughout our Foundation's 60-year history, Floridians have been steadfast supporters of our mission—to eradicate all forms of cancer. We thank you!

Damon Runyon Cancer Research Foundation

675 Third Avenue, New York, New York 10017

NON-PROFIT ORG
US POSTAGE
PAID
PERMIT NO. TK
NEW YORK, N.Y.

broadway bound?

Why pay broker's fees when you can get the best house seats, a tax deduction, and support cutting-edge cancer research at the same time? Use the Damon Runyon Broadway Tickets Service for your personal and business entertaining!

It's easy. Simply call our dedicated Broadway Tickets line at 212.455.0550 between 9 AM and 5 PM, Monday through Friday. Payment can be made by major credit card or by check. Your tickets will be waiting for you at the Box Office on the night of the show.


Catch *Jersey Boys*, *The Drowsy Chaperone*, *Martin Short: Fame Becomes Me* or one of the NEW SHOWS opening in Fall 2006:

A Chorus Line
Butley
The Coast of Utopia
Company
Dr. Seuss' How the Grinch
Stole Christmas
Grey Gardens
High Fidelity

Jay Johnson: The Two
and Only!
Les Misérables
The Little Dog Laughed
Mary Poppins
Spring Awakening
The Times They Are A-Changin'
The Vertical Hour

TO ORDER TICKETS CALL 212.455.0550 or 1.877.7CANCER

(For more information about our Broadway Tickets service, go to our website www.drcrf.org)



GO NO FURTHER FOR TICKETS TO A CHORUS LINE (\$250 EACH)!

Call 212.455.0550 at 9 AM on the first day of each month for your best chance to snag great seats to this season's hottest show.

BAY AREA BOUND? The Damon Runyon Foundation is proud to partner with the Curran Theatre in San Francisco in the recent expansion of our Broadway Tickets service. Seats are available for the Broadway sensation *Jersey Boys* this fall! Call 212.455.0550 to make your reservations.

100% for cancer research

THAT'S HOW MUCH OF YOUR DONATION
WILL BE USED IN THE FIGHT AGAINST CANCER!

giving opportunities

TRIBUTE GIFTS – Honor someone in your life, give special meaning to condolences or celebrate nuptials with a special gift that supports cancer research. The Foundation will send a beautiful card on your behalf to the person(s) of your choosing.

REMEMBER THE FOUNDATION IN YOUR WILL OR TRUST – Support the Damon Runyon Cancer Research Foundation after providing for your family and loved ones. Bequests and trusts using

property, securities or cash provide long-term financial stability to the Foundation.

GIFTS OF SECURITIES – If you have stock that has grown in value and produces little income, you can make a charitable gift of these securities and enjoy significant tax savings.

MATCHING GIFTS – Double your impact through a corporate matching gift. Check with your employer's human

resources department to find out if this is an option for you.

NAMED AWARDS – Sponsor a brilliant scientist for a three-year period or in perpetuity, and we will name the award for you or your family, or in honor of a loved one.

HOST AN EVENT – Help the Foundation reach out to new friends by hosting an event to raise funds and awareness about our important work.

For more information about these giving opportunities, please call 1.877.7CANCER.

Damon Runyon Cancer Research Foundation

EXECUTIVE DIRECTOR

Lorraine W. Egan

675 Third Avenue New York, NY 10017 1.877.7CANCER
Administration 212.455.0500 Fax 212.455.0509
Award Programs 212.455.0520 Fax 212.455.0529
Theatre Ticket Sales 212.455.0550

www.drcrf.org

To receive our newsletter via e-mail, please contact us at 877.7CANCER or info@drcrf.org

Board of Directors

CHAIRMAN
Dale F. Frey

VICE CHAIRMAN—
SCIENTIFIC PROGRAMS
David M. Livingston, MD

VICE CHAIRMAN—
FINANCE AND TREASURER
Leon G. Cooperman

VICE CHAIRMAN—
BOARD DEVELOPMENT
Kenneth G. Langone

VICE CHAIRMAN—
AUDIT AND CORPORATE
GOVERNANCE AND SECRETARY
Sanford W. Morhouse, Esq.

David Baltimore, PhD
Steven J. Burakoff, MD
Gary E. Erlbaum
Thomas J. Fahey, Jr., MD
Elaine V. Fuchs, PhD
Richard B. Gaynor, MD
Margaret A. Gilliam
Michael L. Gordon
Scott Greenstein
Margaret Brennan Hassett
Martha M. Kenny

John P. Keyser
Alan M. Leventhal
Ronald Levy, MD
Anthony F. LoFrisko, Esq.
David G. Marshall
John H. Myers
Richard J. O'Reilly, MD
Katharine F. Plum
Gordon M. Ringold, PhD
Karen D. Seitz
Samuel C. Silverstein, MD
Joel E. Smilow
Craig B. Thompson, MD
August M. Watanabe, MD
Robert C. Wright